Insider Trading Alert - AMTD, LZB And HCN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 8, 2014, 70 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $178.80 to $12,892,563.00.

Highlighted Stocks Traded by Insiders:

TD Ameritrade (AMTD) - FREE Research Report

Marlene M. Ricketts 1994 Dynasty Trust, who is 10% Owner at TD Ameritrade, sold 395,000 shares at $32.64 on Sept. 8, 2014. Following this transaction, the 10% Owner owned 5.2 million shares meaning that the stake was reduced by 7.03% with the 395,000-share transaction.

The shares most recently traded at $32.48, down $0.16, or 0.49% since the insider transaction. Historical insider transactions for TD Ameritrade go as follows:

  • 4-Week # shares sold: 2.6 million
  • 12-Week # shares sold: 2.7 million
  • 24-Week # shares sold: 2.8 million

The average volume for TD Ameritrade has been 2.4 million shares per day over the past 30 days. TD Ameritrade has a market cap of $17.9 billion and is part of the financial sector and financial services industry. Shares are up 6.4% year-to-date as of the close of trading on Monday.

TD Ameritrade Holding Corporation provides securities brokerage services and technology-based financial services to retail investors, traders, and independent registered investment advisors (RIAs) in the United States. The stock currently has a dividend yield of 1.47%. The company has a P/E ratio of 23.3. Currently, there are 12 analysts who rate TD Ameritrade a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMTD - FREE

TheStreet Quant Ratings rates TD Ameritrade as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full TD Ameritrade Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

La-Z-Boy (LZB) - FREE Research Report

Bacon Mark, who is Senior Vice President at La-Z-Boy, sold 22,600 shares at $22.37 on Sept. 8, 2014. Following this transaction, the Senior Vice President owned 96,875 shares meaning that the stake was reduced by 18.92% with the 22,600-share transaction.

The shares most recently traded at $22.02, down $0.35, or 1.58% since the insider transaction. Historical insider transactions for La-Z-Boy go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 46,087
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 54,087
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 54,087

The average volume for La-Z-Boy has been 545,500 shares per day over the past 30 days. La-Z-Boy has a market cap of $1.2 billion and is part of the consumer goods sector and consumer durables industry. Shares are down 27.48% year-to-date as of the close of trading on Monday.

La-Z-Boy Incorporated manufactures, markets, imports, distributes, and retails upholstery furniture products, accessories, and casegoods furniture products in the United States and Canada. The stock currently has a dividend yield of 1.06%. The company has a P/E ratio of 20.4. Currently, there are 5 analysts who rate La-Z-Boy a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LZB - FREE

TheStreet Quant Ratings rates La-Z-Boy as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full La-Z-Boy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Health Care REIT (HCN) - FREE Research Report

Crabtree Michael A, who is Sr. Vice President & Treasurer at Health Care REIT, sold 1,000 shares at $67.41 on Sept. 8, 2014. Following this transaction, the Sr. Vice President & Treasurer owned 49,268 shares meaning that the stake was reduced by 1.99% with the 1,000-share transaction.

The shares most recently traded at $67.23, down $0.18, or 0.27% since the insider transaction. Historical insider transactions for Health Care REIT go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 1,325
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 10,441
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 15,266

The average volume for Health Care REIT has been 1.9 million shares per day over the past 30 days. Health Care REIT has a market cap of $21.1 billion and is part of the financial sector and real estate industry. Shares are up 26.66% year-to-date as of the close of trading on Monday.

Health Care REIT, Inc. is an independent equity real estate investment trust. The firm engages in acquiring, planning, developing, managing, repositioning and monetizing of real estate assets. It primarily invests in the real estate markets of the United States. The stock currently has a dividend yield of 4.65%. The company has a P/E ratio of 131.4. Currently, there are 6 analysts who rate Health Care REIT a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HCN - FREE

TheStreet Quant Ratings rates Health Care REIT as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels, good cash flow from operations, increase in net income and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Health Care REIT Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Video: TD Ameritrade Brings Stock Trading to Twitter

Video: TD Ameritrade Brings Stock Trading to Twitter

Verizon and Yahoo! Sports Bring Super Bowl LII to the Small Screen

Verizon and Yahoo! Sports Bring Super Bowl LII to the Small Screen

Healthcare Panic May Be Overblow; Cryptocurrency Trading Volumes Dip -- ICYMI

Healthcare Panic May Be Overblow; Cryptocurrency Trading Volumes Dip -- ICYMI

Bitcoin Today: Price Predictions Get Bold, Nasdaq Considers New Futures Market

Bitcoin Today: Price Predictions Get Bold, Nasdaq Considers New Futures Market

Cryptocurrency Trading Declining to Start 2018, Says TD Ameritrade CEO

Cryptocurrency Trading Declining to Start 2018, Says TD Ameritrade CEO